Slide 1: Second-Quarter 2026 Results
Second-Quarter 2026 Results August 10, 2026 1
Slide 2: Safe harbor
Safe harbor Forward-looking statements This document contains, and our officers and representatives may from time to time make, certain “forward-looking statements” within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements
Slide 3: Agenda
Agenda 01 Select highlights 02 Sales 03 IFRS results 04 Core results 05 Outlook 3
Slide 4: Q2 2026 Highlights
Q2 2026 Highlights • Sales of $2.8 billion, up 8% on a reported basis, or up 7% constant currency1 (cc), versus second-quarter 2025 • New product launches performing well, including Unity, Valeda, PanOptix Pro, Tryptyr and Systane Pro • Returned $469 million to shareholders via dividends and share r
Slide 5: Select financial highlights
Select financial highlights Net sales Core operating margin1 2Q26 Sales of $2.8B, up 8% y/y on a reported basis; up 7% cc1 2Q26 Operating margin of 0.4%, down 920 2Q26 $2.8B 2Q26 20.6% basis points (bps) y/y; down 930 bps cc2 basis 2Q25 $2.6B 2Q25 19.1% 2Q26 Core operating margin of 20.6%, up 150 bp
Slide 6: Agenda
Agenda 01 Select highlights 02 Sales 03 IFRS results 04 Core results 05 Outlook 6
Slide 7: 1H 2026 Product mix
1H 2026 Product mix1 Vision Care $2.4B (45%) Surgical $3.0B (55%) Ocular health (40%) Implantables (30%) Dry eye products Monofocal IOLs Allergy eye drops Advanced technology IOLs Steroid eye drops Glaucoma implants Glaucoma eye drops Contact lens care Consumables (53%) $5.5 billion Dedicated consum
Slide 8: Q2 2026 Surgical Net Sales
Q2 2026 Surgical Net Sales (USD) (CC)1 (USD $M) $1,455 $1,570 8% 7% $466 2% 1% • Implantables reflects strong performance by PanOptix Pro $456 + • Consumables reflects procedural growth and price increases • Equipment growth reflects recent equipment launches, including the Unity platform $825 6% 5%
Slide 9: Q2 2026 Vision Care Net Sales
Q2 2026 Vision Care Net Sales (USD $M) (USD) (CC)1 $1,122 $1,212 8% 7% • Product innovation and price increases in contact lenses + • Ocular health growth led by our portfolio of dry eye products, including Tryptyr and Systane $692 $726 5% 5% - • Declines in legacy contact lens products $430 $486 13
Slide 10: Agenda
Agenda 01 Select highlights 02 Sales 03 IFRS results 04 Core results 05 Outlook 10
Slide 11: Q2 2026 IFRS results
Q2 2026 IFRS results Worldwide net sales Operating margin Diluted EPS $2.8B $2.6B $0.35 9.6% 0.4% $0.00 2Q25 2Q26 2Q25 2Q26 2Q25 2Q26 1 2 Y/Y change (USD): +8% -920 bps -100% 1. 2Q26 included a pre-tax, non-cash net charge of $402 million related to the discontinuation of the PowerVision programs. 2
Slide 12: 1H 2026 IFRS results
1H 2026 IFRS results Worldwide net sales Operating margin Diluted EPS $5.5B 14.2% $5.0B $1.06 5.5% $0.39 1H25 1H26 1H25 1H26 1H25 1H26 Y/Y change (USD): +9% -870 bps1 -63%1 1. 1H26 included a pre-tax, non-cash net charge of $402 million related to the discontinuation of the PowerVision programs and
Slide 13: Q2 2026 IFRS operating margin bridge
Q2 2026 IFRS operating margin bridge 2Q26 vs. 2Q25, % of net sales 6.3 (0.8) (14.5) 9.6 (0.3) 0.3 0.1 0.4 2 2Q25 Gross SG&A R&D Other income/ Foreign 2Q26 Margin1 expense Exchange 1. 2Q25 included higher amortization of intangibles assets, $44 million of product discontinuation charges and higher in
Slide 14: 1H 2026 IFRS operating margin bridge
1H 2026 IFRS operating margin bridge 1H26 vs. 1H25, % of net sales 3.2 (0.3) 14.2 (7.5) 0.4 5.5 5.1 (4.5) 1H25 Gross SG&A R&D 2 Other income/ Foreign 1H26 Margin1 expense3 Exchange 1. 1H25 included higher amortization of intangible assets and $44 million of product discontinuation charges. 14 2. 1H2
Slide 15: Agenda
Agenda 01 Select highlights 02 Sales 03 IFRS results 04 Core results 05 Outlook 15
Slide 16: Q2 2026 Core results
Q2 2026 Core results1 Worldwide net sales Core operating margin Core diluted EPS $2.8B $2.6B 20.6% $0.84 19.1% $0.76 2Q25 2Q26 2Q25 2Q26 2Q25 2Q26 Y/Y change (cc): +7% +9% +160 bps 1. Core operating margin, core diluted EPS, and constant currency growth, including FX impacts, are non-IFRS measures.
Slide 17: 1H 2026 Core results
1H 2026 Core results1 Worldwide net sales Core operating margin Core diluted EPS $5.5B $5.0B 20.9% $1.69 19.9% $1.50 1H25 1H26 1H25 1H26 1H25 1H26 Y/Y change (cc): +7% +90 bps +10% 17 1. Core operating margin, core diluted EPS, and constant currency growth, including FX impacts, are non-IFRS measure
Slide 18: Q2 2026 Core operating margin bridge
Q2 2026 Core operating margin1 bridge 2Q26 vs. 2Q25, % of net sales 2.5 0.2 20.7 20.6 19.1 (0.9) (0.2) (0.1) 2Q25 Gross Margin SG&A R&D Other income/ Foreign 2Q26 Key drivers expense Exchange • Core operating margin increase as of 2Q26 included manufacturing efficiencies and $15 million of other rev
Slide 19: 1H 2026 Core operating margin bridge
1H 2026 Core operating margin1 bridge 1H26 vs. 1H25, % of net sales 1.1 0.1 20.9 0.2 20.8 0.0 (0.4) 19.9 1H25 Gross Margin SG&A R&D Other income/ Foreign 1H26 expense Exchange Key drivers • Core operating margin increase as 1H26 included manufacturing efficiencies, partially offset by sales and mark
Slide 20: 1H 2026 Cash flow and balance sheet highlights
1H 2026 Cash flow and balance sheet highlights Cash and cash equivalents $1.4 billion 1H26 cash flows from operations $928 million 1H26 free cash flow1 $693 million Capex $235 million Debt $4.7 billion No financial covenants 20 1. Free cash flow is a non-IFRS measure. An explanation of non-IFRS meas
Slide 21: Agenda
Agenda 01 Select highlights 02 Sales 03 IFRS results 04 Core results 05 Outlook 21
Slide 22: FY 2026 Outlook
FY 2026 Outlook 2026 outlook as of May as of August Comments Net sales growth vs. prior year (cc)1 +5% to +7% +5% to +7% Maintained (non-IFRS measure) Core operating margin1 change vs. prior year (cc)1 +70 to +170 bps +90 to +190 bps Increased (non-IFRS measure) Core diluted EPS1 growth vs. prior ye
Slide 23: Appendix
Appendix 23
Slide 24: Non-IFRS measures as defined by the Company
Appendix: Non-IFRS measures as defined by the Company Alcon uses certain non-IFRS metrics when measuring performance, including when measuring current period results against prior periods, including core results, percentage changes measured in constant currencies and free cash flow. Because of their
Slide 25: Reconciliation of IFRS results to core results
Reconciliation of IFRS results to core results (non-IFRS measure) Three months ended June 30, 2026 Amortization of Discontinuation of Core results IFRS certain intangible the PowerVision Efficiency Other (non-IFRS ($ millions except earnings per share) results assets(1) programs(2) measures(6) items
Slide 26: Reconciliation of IFRS results to core results
Reconciliation of IFRS results to core results (non-IFRS measure) Three months ended June 30, 2025 Amortization of Acquisition and Core results IFRS certain intangible integration Product Other (non-IFRS ($ millions except earnings per share) results assets(1) related items(5) Legal items(7) discont
Slide 27: Reconciliation of IFRS results to core results
Reconciliation of IFRS results to core results (non-IFRS measure) Six months ended June 30, 2026 Amortization of Discontinuation of Acquisition and Core results certain intangible the PowerVision integration Efficiency Other (non-IFRS ($ millions except earnings per share) IFRS results assets(1) pro
Slide 28: Reconciliation of IFRS results to core results
Reconciliation of IFRS results to core results (non-IFRS measure) Six months ended June 30, 2025 Amortization Gains on of certain investments in Acquisition and Core results IFRS intangible associated integration Legal Product Other (non-IFRS ($ millions except earnings per share) results assets(1)
Slide 29: Reconciliation of IFRS results to core results
Reconciliation of IFRS results to core results (non-IFRS measure) Explanatory footnotes to IFRS to core reconciliation tables (1) Includes amortization for all intangible assets other than software. (2) For the three and six months ended June 30, 2026, includes a post-tax, non-cash net charge of app
Slide 30: Reconciliation of free cash flow (non-IFRS measure)
Reconciliation of free cash flow (non-IFRS measure) The following is a summary of free cash flow for the six months ended June 30, 2026 and 2025, together with a reconciliation to net cash flows from operating activities, the most directly comparable IFRS measure: ($ millions) 2026 2025 Net cash flo
Slide 31: Alcon
Alcon SEE BRILLIANTLY